Pharmaceutical giant AstraZeneca PLC (AZN.LN) Monday reported positive results from two trials for lung cancer treatments.
It said a Phase III Pacific trial of Imfinzi improved progression-free survival by more than 11 months compared with standard of care. AstraZeneca added that the trial continues to evaluate the other primary endpoint, overall survival.
Continue Reading Below
The company also said a Phase III Flaura trial of Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases.
Tagrisso also showed median progression-free survival of 18.9 months, compared with 10.2 months for the current standard of care, AstraZeneca said.
Write to Ian Walker at firstname.lastname@example.org; @IanWalk40289749
(END) Dow Jones Newswires
September 11, 2017 02:36 ET (06:36 GMT)